EirGenix, Inc. — Investor Relations & Filings
EirGenix, Inc. operates under a dual-engine business model, integrating Contract Development and Manufacturing Organization (CDMO) services with the development of proprietary biologics. The company provides comprehensive solutions spanning cell line development, process optimization, analytical testing, and cGMP-compliant manufacturing for both mammalian and microbial cultures. Its technical infrastructure includes large-scale production capabilities with multiple 2,000-liter single-use bioreactors and advanced continuous manufacturing platforms. EirGenix’s internal pipeline focuses on high-quality biosimilars, notably HER2-targeted therapies for breast cancer, including Trastuzumab biosimilar assets. Additionally, the company produces specialty products such as the CRM197 carrier protein and diagnostic tools. By leveraging integrated development and manufacturing expertise, EirGenix delivers cost-effective biopharmaceutical solutions to support global healthcare needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 114年第4季財務報告書 — 202504_6589_AIC.pdf | 2026-05-05 | Chinese | |
| 114年第4季財務報告書 — 202504_6589_AIA.pdf | 2026-05-05 | Chinese | |
| 114年第4季財務報告書 — 202504_6589_AI3.pdf | 2026-05-05 | Chinese | |
| 114年第4季財務報告書 — 202504_6589_AI1.pdf | 2026-05-05 | Chinese | |
| 114年第4季財務報告書 — 202502_6589_AIA.pdf | 2026-05-05 | Chinese | |
| 114年第4季財務報告書 — 202502_6589_AI1.pdf | 2026-05-05 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41467343 | 114年第4季財務報告書 — 202504_6589_AIC.pdf | 2026-05-05 | Chinese | ||
| 41467309 | 114年第4季財務報告書 — 202504_6589_AIA.pdf | 2026-05-05 | Chinese | ||
| 41467277 | 114年第4季財務報告書 — 202504_6589_AI3.pdf | 2026-05-05 | Chinese | ||
| 41467235 | 114年第4季財務報告書 — 202504_6589_AI1.pdf | 2026-05-05 | Chinese | ||
| 41467055 | 114年第4季財務報告書 — 202502_6589_AIA.pdf | 2026-05-05 | Chinese | ||
| 41467023 | 114年第4季財務報告書 — 202502_6589_AI1.pdf | 2026-05-05 | Chinese | ||
| 41466961 | 114年第4季財務報告書 — 202501_6589_AIA.pdf | 2026-05-05 | Chinese | ||
| 41466923 | 114年第4季財務報告書 — 202501_6589_AI1.pdf | 2026-05-05 | Chinese | ||
| 41467442 | 114年第4季財務報告書 — 202503_6589_AIA.pdf | 2026-05-05 | Chinese | ||
| 41467385 | 114年第4季財務報告書 — 202503_6589_AI1.pdf | 2026-05-05 | Chinese | ||
| 40952762 | 本公司民國115年第一季財務報告 之董事會預計召開日期為民國115年05月12日 | 2026-05-04 | Chinese | ||
| 38523133 | 115年04月法人說明會簡報 — 658920260429E001.pdf | 2026-04-29 | Chinese | ||
| 38522602 | 115年04月法人說明會簡報 — 658920260429M001.pdf | 2026-04-29 | Chinese | ||
| 38522531 | 115年04月法人說明會簡報 | 2026-04-29 | Chinese | ||
| 37952824 | 115年年報及股東會資料 — 2026_6589_20260529FE2.pdf | 2026-04-28 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
|
Adaptimmune Therapeutics PLC
Commercial-stage biopharma developing TCR T-cell therapies …
|
ADAP | GB | Manufacturing |
EirGenix, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52590/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52590 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52590 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52590 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52590}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for EirGenix, Inc. (id: 52590)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.